hero image
Paulo  Verardi, Ph.D. - University of Connecticut. Storrs, CT, US

Paulo Verardi, Ph.D. Paulo  Verardi, Ph.D.

Associate Professor | University of Connecticut


Expert on vaccine development & virology (Smallpox, Rinderpest, Zika, coronaviruses, Rift Valley, Powassan, SFTSV, Heartland, & more)


Dr. Verardi is a virologist who specializes in vaccine research and development. He is an Associate Professor at UConn and a member of the Center of Excellence for Vaccine Research. Dr. Verardi studied Biological Sciences at the Federal University of Rio Grande do Sul in Brazil before earning his Ph.D. in Molecular Virology from the University of California, Davis. He has a broad background in molecular biology, virology, and immunology, with an interest in vaccine and immunotherapeutic vector development. He has worked on vaccinia virus immunomodulating genes, cytokines as attenuating and immunoenhancing agents, the development of a vaccinia virus-based vaccine for rinderpest, safer and more efficacious vaccine vectors for smallpox and AIDS, vaccines and design of safer and diagnostics for Rift Valley fever, foot-and-mouth disease, porcine reproductive and respiratory syndrome, and more recently Zika virus, SARS-CoV-2 (COVID-19), and a number of other mosquito- and tick-borne agents.

Areas of Expertise (8)


Mosquito-borne Diseases

Tick-borne Diseases



Emerging Infectious Diseases



Education (2)

University of California: Ph.D, Comparative Pathology (Molecular Virology) 1997

Federal University of Rio Grande do Sul: B.S., Biological Sciences 1989


Media Appearances (8)

Herd immunity would come with ‘enormous potential human toll’

The New London Day  print


Verardi said we "really didn't have time to develop good antibody tests, and developing good antibody tests is a long process." One issue is there are other coronaviruses, and a test could pick up one of them instead of this one, giving people with positive results a "false sense of security" that they're protected.

view more

Delivering Covid-19 vaccine to 7.8 billion will be the biggest challenge in coming months, warn experts

MEA Worldwide  online


Only a few months into the pandemic, human trials of a few Covid-19 vaccines have already begun. Experts, however, believe that hastening the vaccine development procedures could backfire.

"The vaccine development and approval process is a very long one, mostly because both safety and efficacy must be determined in human clinical trials in a stepwise fashion," Paulo H Verardi, PhD, associate professor of Virology, University of Connecticut told MEA WorldWide (MEAWW). "Trying to do that in the middle of a pandemic, affecting the research and clinical enterprises and with a broken supply chain, makes it even more challenging. And at the end of the day, the safety of the vaccine will be all that matters, so it is important to get it right. That may take several months to a year, at a minimum."

view more

A coronavirus pandemic is sweeping the world, but what exactly is a virus? Is it alive?

USA Today  print


“By themselves, they can’t do anything. They need a host cell to replicate,” virologist Paulo Verardi told USA TODAY. Verardi works on vaccine development and is a University of Connecticut professor.

He suggested thinking of them like a parasite: an organism that survives by harming another species.

view more


UConn Today  


New ticks bring new health concerns. UConn associate professor of pathobiology Paulo Verardi explains the significance of the Asian longhorned tick, and how he and his team have been anticipating the species’ arrival.

view more

Some Antibiotics Rev Up Host Immune Response to Viruses

The Scientist  online


Last week, Paulo Verardi got a paper cut refilling the printer in his office at the University of Connecticut. The virologist started looking through a drawer for some Neosporin, and it got him thinking about what the cream really does. A study he was reading that same day found that treating mice topically with antibiotics in a class known as aminoglycosides—which include neomycin, the antibiotic in Neosporin—helped them fend off infection by some viruses. “This opens our mind to all of these other off-target effects that any drug can have, including antibiotics,” he explains.

view more

Zika: Out Of Sight But Not Out Of Mind For Researchers

Connecticut Public Radio  radio


It’s mosquito season and the Zika virus still remains a threat in many parts of the world — including here in the U.S.

This hour, we hear the latest on efforts to develop a Zika vaccine and we find out what researchers have learned since last summer about how the virus causes microcephaly in newborns.

view more

Zika Starts New Vaccine Race

Hartford Courant  online


"Immediately, since I work in vaccine development, we wanted to start working on a vaccine for Zika," Verardi said. "When we actually made the connection [between Zika and microcephaly] I called them up to my office and said 'There's a grant deadline for UConn tomorrow. … Let's just work on it.' So we spent a lot of time … trying to convince people how significant it was."

view more

At UConn, a Brazilian emigre searches for a way to stop Zika

Boston Globe  online


As a virus called Zika rampaged across his native Brazil last fall, Paulo H. Verardi followed along in the Brazilian newspapers he reads online in his University of Connecticut office. With growing astonishment, he learned that the little-known virus had been linked to a rare and devastating birth defect: babies born with malformed heads and underdeveloped brains.

Verardi, a vaccine researcher, sensed something big was happening — weeks before the US media paid any attention. He had just finished devising a method that could speed an early stage of vaccine development. He needed to test his method on a virus. And he knew the world needed to stop Zika.

view more

Articles (6)

A PRRSV GP5-Mosaic vaccine: Protection of pigs from challenge and ex vivo detection of IFNγ responses against several genotype 2 strains. PLos One

Verardi PH, et al.


Porcine reproductive and respiratory syndrome virus (PRRSV), is a highly mutable RNA virus that affects swine worldwide and its control is very challenging due to its formidable heterogeneity in the field. In the present study, DNA vaccines constructed with PRRSV GP5-Mosaic sequences were complexed to cationic liposomes and administered to experimental pigs by intradermal and intramuscular injection, followed by three boosters 14, 28 and 42 days later.

view more

Antibiotic-dependent expression of early transcription factor subunits leads to stringent control of vaccinia virus replication. Virus Res.

Hagen CJ, Titong A, Sarnoski EA, Verardi PH.


The use of vaccinia virus (VACV) as the vaccine against variola virus resulted in the eradication of smallpox. VACV has since been used in the development of recombinant vaccine and therapeutic vectors, but complications associated with uncontrolled viral replication have constrained its use as a live viral vector.

view more

IL-18 expression results in a recombinant vaccinia virus that is highly attenuated and immunogenic. J Interferon Cytokine Res

Verardi PH, et al.


Interferon-γ (IFN-γ) is an attenuating factor for vaccinia virus (VACV), decreasing its virulence in vivo by more than a million fold. It is also a highly effective adjuvant when administered at the time of immunization with protein antigens. However, recombinant VACV (rVACV) vaccines expressing IFN-γ do not induce enhanced immune responses.

view more

Safety mechanism assisted by the repressor of tetracycline (SMART) vaccinia virus vectors for vaccines and therapeutics. Proc Natl Acad Sci USA.

Verardi PH, et al.


Replication-competent viruses, such as Vaccinia virus (VACV), are powerful tools for the development of oncolytic viral therapies and elicit superior immune responses when used as vaccine and immunotherapeutic vectors. However, severe complications from uncontrolled viral replication can occur, particularly in immunocompromised individuals or in those with other predisposing conditions. VACVs constitutively expressing interferon-γ (IFN-γ) replicate in cell culture indistinguishably from control viruses; however, they replicate in vivo to low or undetectable levels, and are rapidly cleared even in immunodeficient animals.

view more

Use of a recombinant vaccinia virus expressing interferon gamma for post-exposure protection against vaccinia and ectromelia viruses. PLoS One

Verardi PH, et al.


Post-exposure vaccination with vaccinia virus (VACV) has been suggested to be effective in minimizing death if administered within four days of smallpox exposure. While there is anecdotal evidence for efficacy of post-exposure vaccination this has not been definitively studied in humans.

view more

Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice. Proc Natl Acad Sci USA.

Verardi PH, et al.


Rift Valley fever (RVF) is a zoonotic disease endemic in Africa and the Arabian Peninsula caused by the highly infectious Rift Valley fever virus (RVFV) that can be lethal to humans and animals and results in major losses in the livestock industry. RVF is exotic to the United States; however, mosquito species native to this region can serve as biological vectors for the virus.

view more